

Ratliff, Miriam, Dr.med., Dipl.-Biol.

GENERAL INFORMATION



Consultant, Department of Neurosurgery
University Medical Centre Mannheim
Medical Faculty Mannheim Heidelberg University
Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Postdoctoral Fellow
Clinical Cooperation Unit Neurooncology (Prof. Wick, Prof. Winkler)
German Cancer Research Center, DKFZ
69120 Heidelberg

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
1998-2006	Medicine, University of Ulm and Albert-Ludwigs-University Freiburg
2001-2007	Dipl.-Biol. in Neurobiology, University of Ulm

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2016-ongoing	Consultant, Department of Neurosurgery, University Medical Centre Mannheim
2009-2016	Resident, Department of Neurosurgery, Heidelberg University
2007	Dip.-Biol., University of Ulm
2006	Dr.med., Anatomy, Heidelberg University

PROFESSIONAL EXPERIENCE

Year(s)	Education
2016-	Head, Division of Molecular and Translational Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg University Hospital (UKHD), Faculty of Medicine Heidelberg, Heidelberg University
2015-	PI & Head: NCT 3.0 Personalized Radiation Oncology Program (NCT-PRO)
2012-ongoing	Postdoctoral research fellow, Clinical Cooperation Unit Neurooncology, (CCU, Chair Prof. Wick, Prof. Winkler), DKFZ, Heidelberg
2006-2009	Postdoctoral research fellow, Molecular Genetics, (CCU, Chair Prof. L'Hernault), Emory University

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
2019	Psychooncologist (WPO)
2019-2020	Specialist Palliative Care Medicine
currently	Coordinator of student education for the Department of Neurosurgery
currently	physician responsible for sanitation/hygiene
currently	physician responsible for transfusion medicine
currently	substitutional physician responsible for quality management

MEMBERSHIPS

Year(s)	
	Deutsche Gesellschaft für Neurochirurgie (DGNC)
	Neuroonkologischer Arbeitskreis (NOA)
	Deutsche Krebsgesellschaft (DKG)

INVESTIGATOR CLINICAL TRIALS

Year(s)	
	N ² M ² 2015-002752-27 Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without <i>MGMT</i> promoter methylation: NCT; Neuro Master Match; N ² M ² (NOA-20)

	VAXIMM 2017-003076-31 VXM01-AVE-04-INT - An open-label, Phase I/II; multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment, with or without second surgery
	EORTC-1709-BTG 2017-003908-50 A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma

PUBLICATIONS

- 1.) Glutamatergic synaptic input to glioma cells drives tumor progression Venkataramani V, Tanev DI, Strahle C, et al.; *Nature* (2019)
- 2.) Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma. Solecki G, Osswald M, Weber D, et al.; *Cancers* (2019)
- 3.) Suppression of antitumor T cell immunity by the oncometabolite R-2-hydroxyglutarate. Lukas Bunse, Stefan Pusch, Theresa Bunse, et al.; *Nature Medicine* (2018)
- 4.) Neuro-Endocrine Recovery After Pituitary Apoplexy: Prolactin as a Predictive Factor. Lammert A, Walter MS, Giordano FA, et al.; *Exp Clin Endocrinol Diabetes* (2018)
- 5.) MIB-1 is Required for Spermatogenesis and Facilitates LIN-12 and GLP-1 Activity in *C. elegans*. Ratliff M, Hill-Harfe KL, Gleason EJ, et al.; *Genetics* (2018).
- 6.) Tumor Microtubules Convey Resistance to Surgical Lesions and Chemotherapy in Glioma. Weil S, Osswald M, Solecki G, et al.; *Neuro-Oncology* (2017).
- 7.) Ventriculo-bi-leural shunt as last resort in a 4-year-old child in whom a VP and VA shunt failed. Ratliff M, Unterberg A, Bächli H; *Journal of Neurosurgery, Pediatrics* (2015).
- 8.) Brain tumour cells interconnect to a functional and resistant network. Osswald M, Jung E, Sahn F, et al.; *Nature* (2015).
- 9.) Entscheidungskonflikte mit Angehörigen auf der Intensivstation. Ratliff M, Neumann JO; *Intensivmedizin und Notfallmedizin* (2015).
- 10.) Versorgung des Schädel-Hirn-Traumas in der Akutphase. Ratliff M, Unterberg AW; *Thieme – Neuroreha* (2014).
- 11.) Activity-Dependent Shedding of the NMDA Receptor Glycine Binding Site by Matrix Metalloproteinase 3: A Putative Mechanism of Postsynaptic Plasticity. Pauly T*, Ratliff M*, Pietrowski E, Neugebauer R, et al.; *PLoS ONE* (2008).